Clinical Trials Directory

Trials / Completed

CompletedNCT06394921

Cardiopulmonary Exercise Tests in Patients With Long COVID

Interrogative Approaches Identify Causes of Physical Impairment in Those Affected by Post COVID-19 Morbidity (Long COVID) - an International Multicenter Observational Study

Status
Completed
Phase
Study type
Observational
Enrollment
146 (actual)
Sponsor
Sheffield Hallam University · Academic / Other
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Not accepted

Summary

The value of clinical cardiopulmonary exercise testing (CPET) within healthcare settings has been established in the last decade. CPET methods remain highly relevant in the COVID-19 endemic phase and should be used to assess those recovering from COVID-19 (SARS-CoV-2) infection. This diagnostic tool could play an integral role in disease prognostication and evaluate the integrative response to incremental exercise. Date from such assessments can enable practitioners to characterise cardio-respiratory fitness and identify reasons for physical impairment or abnormal cardio-respiratory function. More than 50% of patients admitted to hospital will experience cardiorespiratory issues and significant morbidity during their recovery and will require significant rehabilitative support. In this context, measurements obtained from an assessment of cardio-respiratory responses to physiological stress could provide insight regarding the integrity of the pulmonary-vascular interface and characterisation of any impairment or abnormal cardio-respiratory function. Current approaches to rehabilitation are being developed on existing knowledge from Severe Acute Respiratory Syndrome (SARS) and Acute Respiratory Distress Syndrome (ARDS) related illness. These provide important insight but do not provide insight into the novel challenges provided by COVID-19.

Conditions

Interventions

TypeNameDescription
PROCEDURE2 day cardiopulmonary exercise testConsecutive day 2 day CPET and follow up for 7 days for subjective feelings/fatigue.

Timeline

Start date
2023-03-01
Primary completion
2024-04-30
Completion
2024-04-30
First posted
2024-05-01
Last updated
2024-08-22

Locations

5 sites across 3 countries: United States, India, United Kingdom

Source: ClinicalTrials.gov record NCT06394921. Inclusion in this directory is not an endorsement.